Response to letters regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement"

Circulation. 2015 Sep 29;132(13):e166-7. doi: 10.1161/CIRCULATIONAHA.115.016779.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aspirin / therapeutic use*
  • Coronary Disease / therapy*
  • Drug-Eluting Stents*
  • Female
  • Humans
  • Male
  • Paclitaxel / therapeutic use*
  • Piperazines / therapeutic use*
  • Purinergic P2Y Receptor Antagonists / therapeutic use*
  • Thiophenes / therapeutic use*

Substances

  • Piperazines
  • Purinergic P2Y Receptor Antagonists
  • Thiophenes
  • Paclitaxel
  • Aspirin